HRP20231264T1 - Protutijela protiv csf-1r - Google Patents
Protutijela protiv csf-1r Download PDFInfo
- Publication number
- HRP20231264T1 HRP20231264T1 HRP20231264TT HRP20231264T HRP20231264T1 HR P20231264 T1 HRP20231264 T1 HR P20231264T1 HR P20231264T T HRP20231264T T HR P20231264TT HR P20231264 T HRP20231264 T HR P20231264T HR P20231264 T1 HRP20231264 T1 HR P20231264T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- cancer
- binding fragment
- fibrosis
- heavy chain
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 238000010367 cloning Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000013599 cloning vector Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003140 astrocytic effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Claims (18)
1. Anti-CSF-IR protutijelo ili njegov vezni fragment koji sadrži teški lanac i laki lanac, naznačeno time što varijabilna domena teškog lanca sadrži sekvencu navedenu u SEQ ID NO: 23 i pri čemu varijabilna domena lakog lanca sadrži sekvencu navedenu u SEQ ID NO:15.
2. Anti-CSF-1R protutijelo ili njegov vezni fragment prema zahtjevu 1, naznačeno time što je protutijelo kompletna molekula protutijela koja sadrži teške i lake lance pune dužine ili je vezni fragment protutijela, pri čemu vezni fragment sadrži Fab, modificirani Fab', Fab', F(ab')2, Fv, ili scFv fragment.
3. Anti-CSF-1R protutijelo ili njegov vezni fragment prema zahtjevu 1 ili zahtjevu 2, naznačeno time što je protutijelo vezni fragment koji sadrži konstantnu domenu CH1 teškog lanca i konstantnu domenu CL lakog lanca.
4. Anti-CSF-1R protutijelo prema bilo kojem od zahtjeva 1 do 3, koje ima teški lanac koji sadrži sekvencu navedenu u SEQ ID NO: 27 i laki lanac koji sadrži sekvencu navedenu u SEQ ID NO:19, naznačeno time što je C-terminalni lizin teškog lanca protutijela odsutan.
5. Anti-CSF-1R protutijelo ili njegov vezni fragment prema bilo kojem od zahtjeva 1 do 4, naznačeno time što ima na njega vezanu efektorsku ili reportersku molekulu.
6. Prva izolirana sekvenca DNA koja kodira teški lanac i druga izolirana sekvenca DNA koja kodira laki lanac protutijela ili njegovog veznog fragmenta prema bilo kojem od zahtjeva 1 do 5.
7. Vektor za kloniranje ili ekspresiju koji sadrži prvu izoliranu sekvencu DNA koja kodira teški lanac i drugu izoliranu sekvencu DNA koja kodira laki lanac prema zahtjevu 6.
8. Prvi vektor za kloniranje ili ekspresiju koji sadrži prvu izoliranu sekvencu DNA koja kodira teški lanac i drugi vektor za kloniranje ili ekspresiju koji sadrži drugu izoliranu sekvencu DNA koja kodira laki lanac prema zahtjevu 6.
9. Vektor prema zahtjevu 7 ili zahtjevu 8, naznačen time što vektor sadrži sekvence navedene u SEQ ID NO:24 i SEQ ID NO:16.
10. Stanica domaćina naznačena time što sadrži vektore za kloniranje ili ekspresiju prema zahtjevu 7 ili zahtjevu 8.
11. In vitro postupak za proizvodnju protutijela ili njegovog veznog fragmenta prema bilo kojem od zahtjeva 1 do 5, naznačen time što se sastoji od uzgoja stanice domaćina prema zahtjevu 9 i izolacije protutijela ili njegovog veznog fragmenta.
12. Farmaceutski pripravak koji sadrži protutijelo ili njegov vezni fragment prema bilo kojem od zahtjeva 1 do 5, u kombinaciji s jednom ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili nosača.
13. Farmaceutski pripravak prema zahtjevu 12, naznačen time što dodatno sadrži druge aktivne sastojke.
14. Protutijelo ili njegov vezni fragment prema bilo kojem od zahtjeva 1 do 5 ili pripravak prema zahtjevu 12 ili 13 za upotrebu kao lijek.
15. Protutijelo ili njegov vezni fragment prema bilo kojem od zahtjeva 1 do 5 ili pripravak prema zahtjevu 12 ili 13 za upotrebu u liječenju raka.
16. Protutijelo ili njegov vezni fragment prema bilo kojem od zahtjeva 1 do 5 ili pripravak prema zahtjevu 12 ili 13, za upotrebu u liječenju fibrotične bolesti.
17. Protutijelo ili njegov vezni fragment za upotrebu prema zahtjevu 15, naznačeno time što je rak odabran iz skupine koju čine rak dojke, rak prostate, rak kostiju, kolorektalni karcinom, leukemija, limfom, rak kože, rak jednjaka, rak želuca, astrocitni karcinom, rak endometrija, rak vrata maternice, rak mokraćnog mjehura, rak bubrega, rak pluća, rak jetre, rak štitnjače, rak glave i vrata, rak gušterače i rak jajnika.
18. Protutijelo ili njegov vezni fragment za upotrebu prema zahtjevu 16, naznačeno time što je fibrotična bolest odabrana iz skupine koju čine plućna fibroza kao što je idiopatska plućna fibroza i cistična fibroza, bubrežna fibroza, ciroza jetre, endomiokardijalna fibroza, medijastinalna fibroza, mijelofibroza, retroperitonealna fibroza, progresivna masivna fibroza, nefrogena sistemska fibroza, Crohnova bolest, keloid, infarkt miokarda, sklerodermija i artofibroza.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1315487.7A GB201315487D0 (en) | 2013-08-30 | 2013-08-30 | Antibodies |
EP19171833.7A EP3549599B1 (en) | 2013-08-30 | 2014-08-26 | Antibodies against csf-1r |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231264T1 true HRP20231264T1 (hr) | 2024-02-02 |
Family
ID=49397073
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231264TT HRP20231264T1 (hr) | 2013-08-30 | 2014-08-26 | Protutijela protiv csf-1r |
HRP20191051TT HRP20191051T1 (hr) | 2013-08-30 | 2019-06-12 | Antitijela protiv csf-1r |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191051TT HRP20191051T1 (hr) | 2013-08-30 | 2019-06-12 | Antitijela protiv csf-1r |
Country Status (39)
Country | Link |
---|---|
US (2) | US9908939B2 (hr) |
EP (3) | EP3038643B1 (hr) |
JP (3) | JP6632075B2 (hr) |
KR (1) | KR102303130B1 (hr) |
CN (2) | CN112321711A (hr) |
AR (1) | AR097464A1 (hr) |
AU (1) | AU2014314304B2 (hr) |
BR (1) | BR112016004324B1 (hr) |
CA (1) | CA2922240C (hr) |
CL (1) | CL2016000438A1 (hr) |
CY (1) | CY1121964T1 (hr) |
DK (2) | DK3549599T3 (hr) |
EA (1) | EA036255B1 (hr) |
ES (2) | ES2965207T3 (hr) |
FI (1) | FI3549599T3 (hr) |
GB (1) | GB201315487D0 (hr) |
HK (1) | HK1220142A1 (hr) |
HR (2) | HRP20231264T1 (hr) |
HU (2) | HUE045672T2 (hr) |
IL (1) | IL244043B (hr) |
LT (2) | LT3038643T (hr) |
MA (2) | MA44922B1 (hr) |
MX (1) | MX2016002166A (hr) |
MY (1) | MY172484A (hr) |
NZ (1) | NZ717399A (hr) |
PE (2) | PE20201067A1 (hr) |
PH (1) | PH12016500275A1 (hr) |
PL (2) | PL3038643T3 (hr) |
PT (2) | PT3038643T (hr) |
RS (2) | RS64784B1 (hr) |
SG (1) | SG11201601151PA (hr) |
SI (2) | SI3038643T1 (hr) |
TN (1) | TN2016000067A1 (hr) |
TR (1) | TR201909478T4 (hr) |
TW (1) | TWI531582B (hr) |
UA (1) | UA118354C2 (hr) |
UY (1) | UY35718A (hr) |
WO (1) | WO2015028455A1 (hr) |
ZA (1) | ZA201601437B (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
MX2017014782A (es) * | 2015-05-27 | 2018-02-15 | Ucb Biopharma Sprl | Metodo para el tratamiento de enfermedad neurologica. |
EP3302552A1 (en) * | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
CA3063718A1 (en) * | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
GB201803226D0 (en) * | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术(南京)有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
CN108948198B (zh) * | 2018-07-18 | 2020-09-01 | 博奥信生物技术(南京)有限公司 | 抗人csf-1r单克隆抗体及其应用 |
US20220064310A1 (en) * | 2018-12-13 | 2022-03-03 | Development Center For Biotechnology | Anti-human csf-1r antibody and uses thereof |
WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
CA3162403A1 (en) * | 2019-12-24 | 2021-07-01 | Fangyong Du | Anti-csf1r molecules and use thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
PT1570267E (pt) | 2002-12-03 | 2012-01-03 | Ucb Pharma Sa | Ensaio para a identificação de células produtoras de anticorpos |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005003169A2 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
PL2188313T3 (pl) * | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
JP5592792B2 (ja) | 2007-09-26 | 2014-09-17 | ユセベ ファルマ ソシエテ アノニム | 二重特異性抗体の融合体 |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
KR101633520B1 (ko) * | 2008-03-14 | 2016-06-24 | 트랜스진 에스.에이. | Csf-1r에 대한 항체 |
US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
US20120283415A1 (en) | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
ES2557454T3 (es) | 2009-12-10 | 2016-01-26 | F. Hoffmann-La Roche Ag | Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
EP2542588A1 (en) * | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
EP2542587A1 (en) * | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
RS58211B1 (sr) * | 2010-05-04 | 2019-03-29 | Five Prime Therapeutics Inc | Antitela koja vezuju csf1r |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
-
2013
- 2013-08-30 GB GBGB1315487.7A patent/GB201315487D0/en not_active Ceased
-
2014
- 2014-08-05 TW TW103126815A patent/TWI531582B/zh active
- 2014-08-26 MA MA44922A patent/MA44922B1/fr unknown
- 2014-08-26 MX MX2016002166A patent/MX2016002166A/es active IP Right Grant
- 2014-08-26 PT PT14755668T patent/PT3038643T/pt unknown
- 2014-08-26 ES ES19171833T patent/ES2965207T3/es active Active
- 2014-08-26 JP JP2016537262A patent/JP6632075B2/ja active Active
- 2014-08-26 US US14/914,676 patent/US9908939B2/en active Active
- 2014-08-26 PL PL14755668T patent/PL3038643T3/pl unknown
- 2014-08-26 UA UAA201601175A patent/UA118354C2/uk unknown
- 2014-08-26 EP EP14755668.2A patent/EP3038643B1/en active Active
- 2014-08-26 CA CA2922240A patent/CA2922240C/en active Active
- 2014-08-26 EP EP19171833.7A patent/EP3549599B1/en active Active
- 2014-08-26 DK DK19171833.7T patent/DK3549599T3/da active
- 2014-08-26 SI SI201431235T patent/SI3038643T1/sl unknown
- 2014-08-26 PE PE2020000532A patent/PE20201067A1/es unknown
- 2014-08-26 LT LTEP14755668.2T patent/LT3038643T/lt unknown
- 2014-08-26 PE PE2016000313A patent/PE20160528A1/es unknown
- 2014-08-26 TN TN2016000067A patent/TN2016000067A1/en unknown
- 2014-08-26 PL PL19171833.7T patent/PL3549599T3/pl unknown
- 2014-08-26 TR TR2019/09478T patent/TR201909478T4/tr unknown
- 2014-08-26 RS RS20230962A patent/RS64784B1/sr unknown
- 2014-08-26 HR HRP20231264TT patent/HRP20231264T1/hr unknown
- 2014-08-26 LT LTEP19171833.7T patent/LT3549599T/lt unknown
- 2014-08-26 KR KR1020167007073A patent/KR102303130B1/ko active IP Right Grant
- 2014-08-26 WO PCT/EP2014/068050 patent/WO2015028455A1/en active Application Filing
- 2014-08-26 BR BR112016004324-3A patent/BR112016004324B1/pt active IP Right Grant
- 2014-08-26 CN CN202011009068.8A patent/CN112321711A/zh active Pending
- 2014-08-26 HU HUE14755668A patent/HUE045672T2/hu unknown
- 2014-08-26 CN CN201480057403.8A patent/CN105658236B/zh active Active
- 2014-08-26 SI SI201432048T patent/SI3549599T1/sl unknown
- 2014-08-26 EA EA201690503A patent/EA036255B1/ru not_active IP Right Cessation
- 2014-08-26 RS RS20190833A patent/RS59019B1/sr unknown
- 2014-08-26 HU HUE19171833A patent/HUE064437T2/hu unknown
- 2014-08-26 EP EP23192221.2A patent/EP4282881A3/en active Pending
- 2014-08-26 NZ NZ717399A patent/NZ717399A/en unknown
- 2014-08-26 DK DK14755668.2T patent/DK3038643T3/da active
- 2014-08-26 AU AU2014314304A patent/AU2014314304B2/en active Active
- 2014-08-26 MY MYPI2016700624A patent/MY172484A/en unknown
- 2014-08-26 MA MA38930A patent/MA38930A1/fr unknown
- 2014-08-26 FI FIEP19171833.7T patent/FI3549599T3/fi active
- 2014-08-26 ES ES14755668T patent/ES2733735T3/es active Active
- 2014-08-26 PT PT191718337T patent/PT3549599T/pt unknown
- 2014-08-26 SG SG11201601151PA patent/SG11201601151PA/en unknown
- 2014-08-27 AR ARP140103206A patent/AR097464A1/es unknown
- 2014-08-29 UY UY35718A patent/UY35718A/es not_active Application Discontinuation
-
2016
- 2016-02-09 IL IL244043A patent/IL244043B/en active IP Right Grant
- 2016-02-10 PH PH12016500275A patent/PH12016500275A1/en unknown
- 2016-02-25 CL CL2016000438A patent/CL2016000438A1/es unknown
- 2016-03-02 ZA ZA2016/01437A patent/ZA201601437B/en unknown
- 2016-07-15 HK HK16108335.9A patent/HK1220142A1/zh unknown
-
2018
- 2018-01-30 US US15/883,130 patent/US10421814B2/en active Active
-
2019
- 2019-06-12 HR HRP20191051TT patent/HRP20191051T1/hr unknown
- 2019-07-23 CY CY20191100779T patent/CY1121964T1/el unknown
- 2019-09-13 JP JP2019166697A patent/JP7195237B2/ja active Active
-
2021
- 2021-09-17 JP JP2021152574A patent/JP2022002523A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231264T1 (hr) | Protutijela protiv csf-1r | |
HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
HRP20200906T1 (hr) | Il-18 vezujuće molekule | |
RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
HRP20200164T1 (hr) | Bispecifična protutijela koja se vežu na cd38 i cd3 | |
JP2020501532A5 (hr) | ||
HRP20230078T1 (hr) | Sredstva za vezivanje vegf/dll4 i njihova uporaba | |
JP2016196468A5 (hr) | ||
HRP20202024T1 (hr) | Cd3-vežuća domena | |
HRP20191129T1 (hr) | Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora | |
JP2016185981A5 (hr) | ||
IL256871B2 (en) | Constructs for bispecific antibodies binding to dll3 and cd3 and uses thereof | |
JP2016053091A5 (hr) | ||
JP2018504105A5 (hr) | ||
HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
EA201790986A1 (ru) | Антитела к cd73 и их применения | |
JP2014088414A5 (hr) | ||
RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
JP2013539369A5 (hr) | ||
RU2017102312A (ru) | Конструкции мультиспецифичных антител | |
JP2015146822A5 (hr) | ||
CA2699834A1 (en) | Improved anti-il-6 receptor antibody | |
MX2023009050A (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. | |
JP2013166763A5 (hr) | ||
HRP20210120T1 (hr) | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti |